SCHEMBL4850248

SCHEMBL4850248

CN(C)C(=O)Cc1ccc2c(c1)NC(=O)c1ccc(-c3ccnc(F)c3)cc1N2

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 16/20 0.64
CDC7 O00311 3/20 0.47
ROCK2 O75116 3/20 0.47
MAP4K4 O95819 3/20 0.47
CDK2 P24941 3/20 0.47
GSK3B P49841 3/20 0.47
CLK4 Q9HAZ1 3/20 0.47
IRAK4 Q9NWZ3 3/20 0.47
MKNK2 Q9HBH9 1/20 0.47
PRKACA P17612 2/20 0.43
ABL1 P00519 1/20 0.42
HIPK2 Q9H2X6 1/20 0.39
CHEK2 O96017 1/20 0.39
KIT P10721 1/20 0.39
MARK3 P27448 1/20 0.39
MAPK1 P28482 1/20 0.39
AKT1 P31749 1/20 0.39
MARK2 Q7KZI7 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858583 0.88 CHEK1 (0.49) CHEK1CDC7ROCK2MAP4K4CDK2
SCHEMBL4852610 0.82 CHEK1 (0.68) CHEK1MAP4K4CDK2CLK4IRAK4
SCHEMBL4851403 0.80 ABL1 (0.54) CHEK1ROCK2CDK2GSK3BIRAK4
SCHEMBL4852322 0.78 MAP4K4 (0.51) CHEK1CDC7ROCK2MAP4K4CDK2
SCHEMBL4856953 0.78 CHEK1 (0.79) CHEK1ROCK2MAP4K4CDK2GSK3B
SCHEMBL4850428 0.77 CDC7 (0.71) CHEK1CDC7ROCK2MAP4K4CDK2
SCHEMBL4859172 0.77 CHEK1 (0.50) CHEK1CDC7ROCK2MAP4K4CDK2
SCHEMBL4852506 0.77 CHEK1 (0.80) CHEK1ROCK2MAP4K4GSK3BCLK4
SCHEMBL4854806 0.75 CHEK1 (0.77) CHEK1CDC7ROCK2MAP4K4CDK2
SCHEMBL4858287 0.75 CHEK1 (1.00) CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 CHEK1 46/4885CDC7 49/4885ROCK2 486/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885CDC7 50/4885ROCK2 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.